OLD Mission Capital LLC Invests $2.33 Million in Genmab A/S (NASDAQ:GMAB)

OLD Mission Capital LLC purchased a new position in shares of Genmab A/S (NASDAQ:GMAB) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 111,601 shares of the company’s stock, valued at approximately $2,329,000.

Several other institutional investors have also recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC grew its stake in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after purchasing an additional 939 shares during the last quarter. Lindbrook Capital LLC grew its position in Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after buying an additional 950 shares during the last quarter. GAMMA Investing LLC increased its stake in Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after buying an additional 1,051 shares during the period. Cromwell Holdings LLC raised its position in Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after buying an additional 2,496 shares during the last quarter. Finally, R Squared Ltd acquired a new stake in shares of Genmab A/S in the 4th quarter worth $93,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Performance

Genmab A/S stock opened at $18.66 on Wednesday. The firm has a market capitalization of $12.35 billion, a price-to-earnings ratio of 10.72, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. Genmab A/S has a fifty-two week low of $18.50 and a fifty-two week high of $30.50. The stock’s fifty day moving average is $20.81 and its two-hundred day moving average is $21.73.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, sell-side analysts forecast that Genmab A/S will post 1.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on GMAB shares. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target for the company in a report on Thursday, February 13th. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Finally, Truist Financial reduced their target price on Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Genmab A/S currently has an average rating of “Moderate Buy” and an average price target of $41.33.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.